
## Rhonda M Cooper-Dehoff

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4884197/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tight Blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients With Diabetes and Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2010, 304, 61.	3.8	578
2	Multisite Investigation of Outcomes WithÂlmplementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 181-191.	1.1	213
3	Hypertension Across a Woman'sÂLifeÂCycle. Journal of the American College of Cardiology, 2018, 71, 1797-1813.	1.2	159
4	The Clinical Pharmacogenetics Implementation Consortium Guideline for <i>SLCO1B1</i> , <i>ABCG2</i> , and <i>CYP2C9</i> genotypes and Statinâ€Associated Musculoskeletal Symptoms. Clinical Pharmacology and Therapeutics, 2022, 111, 1007-1021.	2.3	120
5	Challenges and strategies for implementing genomic services in diverse settings: experiences from the Implementing GeNomics In pracTicE (IGNITE) network. BMC Medical Genomics, 2017, 10, 35.	0.7	99
6	Hypertension pharmacogenomics: in search of personalized treatment approaches. Nature Reviews Nephrology, 2016, 12, 110-122.	4.1	90
7	Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. Journal of Hypertension, 2014, 32, 635-643.	0.3	88
8	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes and Endocrinology,the, 2017, 5, 534-543.	5.5	84
9	2014 Eighth Joint National Committee Panel Recommendation for BloodÂPressureÂTargets Revisited. Journal of the American College of Cardiology, 2014, 64, 784-793.	1.2	67
10	Cardiovascular Disease and 10-Year Mortality in Postmenopausal Women with Clinical Features of Polycystic Ovary Syndrome. Journal of Women's Health, 2016, 25, 875-881.	1.5	65
11	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. European Heart Journal, 2021, 42, 1742-1756.	1.0	63
12	Impact of Abdominal Obesity on Incidence of Adverse Metabolic Effects Associated With Antihypertensive Medications. Hypertension, 2010, 55, 61-68.	1.3	60
13	Branched-chain amino acid, meat intake and risk of type 2 diabetes in the Women's Health Initiative. British Journal of Nutrition, 2017, 117, 1523-1530.	1.2	60
14	Rationale and design of the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD (WARRIOR) trial. American Heart Journal, 2021, 237, 90-103.	1.2	51
15	Cardiovascular Therapies and Associated Glucose Homeostasis. Journal of the American College of Cardiology, 2009, 53, S28-S34.	1.2	47
16	Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to Î <sup>2</sup> -Blockers in Hypertensive African Americans. Hypertension, 2016, 67, 556-563.	1.3	41
17	INVEST revisited: review of findings from the International Verapamil SR–Trandolapril Study. Expert Review of Cardiovascular Therapy, 2009, 7, 1329-1340.	0.6	36
18	Vascular Smooth Muscle Cells From Hypertensive Patient-Derived Induced Pluripotent Stem Cells to Advance Hypertension Pharmacogenomics. Stem Cells Translational Medicine, 2015, 4, 1380-1390.	1.6	36

#	Article	IF	CITATIONS
19	Genome-wide study of resistant hypertension identified from electronic health records. PLoS ONE, 2017, 12, e0171745.	1.1	36
20	Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide. Hypertension, 2017, 69, 51-59.	1.3	34
21	Aldosterone inhibition and coronary endothelial function in women without obstructive coronary artery disease: An ancillary study of the National Heart, Lung, and Blood Institute–sponsored Women's Ischemia Syndrome Evaluation. American Heart Journal, 2014, 167, 826-832.	1.2	33
22	Largeâ€Scale Geneâ€Centric Analysis Identifies Polymorphisms for Resistant Hypertension. Journal of the American Heart Association, 2014, 3, e001398.	1.6	32
23	Association between high sensitivity C-reactive protein and metabolic syndrome in subjects completing the National Health and Nutrition Examination Survey (NHANES) 2009–10. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2014, 8, 88-90.	1.8	25
24	Long-Term Mortality in Hypertensive Patients With Coronary Artery Disease. Hypertension, 2016, 68, 1110-1114.	1.3	25
25	How to Transition from Singleâ€Gene Pharmacogenetic Testing to Preemptive Panelâ€Based Testing: A Tutorial. Clinical Pharmacology and Therapeutics, 2020, 108, 557-565.	2.3	24
26	A Genetic Response Score for Hydrochlorothiazide Use. Hypertension, 2016, 68, 621-629.	1.3	21
27	Genomeâ€Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to βâ€Blockers. Journal of the American Heart Association, 2018, 7, .	1.6	18
28	Establishing the value of genomics in medicine: the IGNITE Pragmatic Trials Network. Genetics in Medicine, 2021, 23, 1185-1191.	1.1	17
29	Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. PLoS ONE, 2021, 16, e0248080.	1.1	17
30	Blood pressure lowering in patients with diabetes—one level might not fit all. Nature Reviews Cardiology, 2011, 8, 42-49.	6.1	16
31	Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD. American Journal of Medicine, 2018, 131, 1463-1472.e7.	0.6	16
32	Genome-wide association analysis of common genetic variants of resistant hypertension. Pharmacogenomics Journal, 2019, 19, 295-304.	0.9	16
33	The PCORnet Blood Pressure Control Laboratory. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006115.	0.9	16
34	Genetic loci associated with nonobstructive coronary artery disease in Caucasian women. Physiological Genomics, 2016, 48, 12-20.	1.0	15
35	Genetic Variants Associated With Uncontrolled Blood Pressure onÂThiazide Diuretic/βâ€Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses)Âand INVEST (International Verapamil‧R Trandolapril Study) Trials. Journal of the American Heart Association. 2017. 6.	1.6	15
36	Hypertension in Florida: Data From the OneFlorida Clinical Data Research Network. Preventing Chronic Disease, 2018, 15, E27.	1.7	15

#	Article	IF	CITATIONS
37	Incidence, prevalence, and predictors of treatmentâ€resistant hypertension with intensive blood pressure lowering. Journal of Clinical Hypertension, 2019, 21, 825-834.	1.0	15
38	Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol. Metabolomics, 2016, 12, 1.	1.4	14
39	Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women's Heart Disease. Journal of Women's Health, 2016, 25, 996-1003.	1.5	14
40	Gene Variants at Loci Related to Blood Pressure Account for Variation in Response to Antihypertensive Drugs Between Black and White Individuals. Hypertension, 2019, 74, 614-622.	1.3	14
41	Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease. Journal of Clinical Hypertension, 2019, 21, 91-101.	1.0	14
42	Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis. American Journal of Medicine, 2019, 132, 172-174.	0.6	14
43	Effect of plasma MicroRNA on antihypertensive response to beta blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies. European Journal of Pharmaceutical Sciences, 2019, 131, 93-98.	1.9	13
44	Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across <i>CYP2D6</i> Genotypeâ€Derived Activity Scores. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 678-685.	1.3	13
45	Calcium antagonists in the treatment of coronary artery disease. Current Opinion in Pharmacology, 2013, 13, 301-308.	1.7	12
46	Optimizing identification of resistant hypertension: Computable phenotype development and validation. Pharmacoepidemiology and Drug Safety, 2020, 29, 1393-1401.	0.9	12
47	Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center. Cardio-Oncology, 2021, 7, 10.	0.8	12
48	Optimizing Antihypertensive Medication Classification in Electronic Health Record-Based Data: Classification System Development and Methodological Comparison. JMIR Medical Informatics, 2020, 8, e14777.	1.3	12
49	Tracking Blood Pressure Control Performance and Process Metrics in 25 US Health Systems: The PCORnet Blood Pressure Control Laboratory. Journal of the American Heart Association, 2021, 10, e022224.	1.6	12
50	Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension. Journal of Clinical Hypertension, 2017, 19, 1301-1308.	1.0	11
51	Relationships between components of metabolic syndrome and coronary intravascular ultrasound atherosclerosis measures in women without obstructive coronary artery disease. Cardiovascular Endocrinology, 2015, 4, 45-52.	0.8	10
52	Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach. Metabolomics, 2016, 12, 1.	1.4	10
53	New Drug Approvals in 2018 – Another Record Year!. American Journal of Medicine, 2019, 132, 1038-1043.	0.6	10
54	Generic Drugs for Hypertension: Are They Really Equivalent?. Current Hypertension Reports, 2013, 15, 340-345.	1.5	9

#	Article	IF	CITATIONS
55	β <sub>2</sub> â€Adrenergic Receptor Gene Affects the Heart Rate Response of βâ€Blockers: Evidence From 3 Clinical Studies. Journal of Clinical Pharmacology, 2019, 59, 1462-1470.	1.0	9
56	Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension. American Journal of Hypertension, 2019, 32, 668-675.	1.0	9
57	Comparison of Blood Pressure Control Rates Among Recommended Drug Selection Strategies for Initial Therapy of Hypertension. American Journal of Hypertension, 2016, 29, 1186-1194.	1.0	8
58	Attended vs unattended systolic blood pressure measurement: A randomized comparison in patients with cardiovascular disease. Journal of Clinical Hypertension, 2020, 22, 1987-1992.	1.0	8
59	Sorting nexin 1 loss results in increased oxidative stress and hypertension. FASEB Journal, 2020, 34, 7941-7957.	0.2	8
60	Impact of Aspirin According to Type of Stable Coronary Artery Disease: Insights from a Large International Cohort. American Journal of Medicine, 2015, 128, 137-143.	0.6	7
61	Multiplex SNaPshot—a new simple and efficient CYP2D6 and ADRB1 genotyping method. Human Genomics, 2016, 10, 11.	1.4	7
62	Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers. PLoS ONE, 2019, 14, e0221957.	1.1	7
63	New Drugs Approved in 2019. American Journal of Medicine, 2020, 133, 675-678.	0.6	7
64	Metabolomics Signature of Plasma Renin Activity and Linkage with Blood Pressure Response to Beta Blockers and Thiazide Diuretics in Hypertensive European American Patients. Metabolites, 2021, 11, 645.	1.3	7
65	New Drugs Approved in 2021. American Journal of Medicine, 2022, , .	0.6	7
66	Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies. BMC Medical Genomics, 2018, 11, 55.	0.7	6
67	Multi-Institutional Implementation of Clinical Decision Support for APOL1, NAT2, and YEATS4 Genotyping in Antihypertensive Management. Journal of Personalized Medicine, 2021, 11, 480.	1.1	6
68	Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genomeâ€Wide Interaction Metaâ€Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies. Clinical Pharmacology and Therapeutics, 2021, 110, 723-732.	2.3	6
69	Intensive blood pressure lowering reduces adverse cardiovascular outcomes among patients with highâ€normal glucose: An analysis from the Systolic Blood Pressure Intervention Trial database. Journal of Clinical Hypertension, 2018, 20, 620-624.	1.0	5
70	Mortality implications of lower DBP with lower achieved systolic pressures in coronary artery disease. Journal of Hypertension, 2018, 36, 419-427.	0.3	5
71	Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting. American Journal of Hypertension, 2020, 33, 316-324.	1.0	5
72	Systolic blood pressure, heart rate, and outcomes in patients with coronary disease and heart failure. ESC Heart Failure, 2020, 7, 124-130.	1.4	5

#	Article	IF	CITATIONS
73	Potential of Minocycline for Treatment of Resistant Hypertension. American Journal of Cardiology, 2021, 156, 147-149.	0.7	5
74	Effects of Verapamil SR and Atenolol on 24-Hour Blood Pressure and Heart Rate in Hypertension Patients with Coronary Artery Disease: An International Verapamil SR-Trandolapril Ambulatory Monitoring Substudy. PLoS ONE, 2015, 10, e0122726.	1.1	4
75	Objectively measured pediatric obesity prevalence using the OneFlorida Clinical Research Consortium. Obesity Research and Clinical Practice, 2019, 13, 12-15.	0.8	4
76	Alteration in fasting glucose after prolonged treatment with a thiazide diuretic. Diabetes Research and Clinical Practice, 2014, 104, 363-369.	1.1	3
77	2017 Is Banner Year for Drug Approvals by the Food and Drug Administration. American Journal of Medicine, 2018, 131, 1025-1033.	0.6	3
78	Race-Specific Comparisons of Antihypertensive and Metabolic Effects of Hydrochlorothiazide and Chlorthalidone. American Journal of Medicine, 2021, 134, 918-925.e2.	0.6	3
79	New Drugs Approved in 2020. American Journal of Medicine, 2021, 134, 1096-1100.	0.6	3
80	Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and COVID-19-related outcomes: A patient-level analysis of the PCORnet blood pressure control lab. American Heart Journal Plus, 2022, 13, 100112.	0.3	3
81	Redefining Resistant Hypertension. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e005979.	0.9	2
82	Assessment of a Manual Method versus an Automated, Probability-Based Algorithm to Identify Patients at High Risk for Pharmacogenomic Adverse Drug Outcomes in a University-Based Health Insurance Program. Journal of Personalized Medicine, 2022, 12, 161.	1.1	2
83	Serotonin Transporter Gene Polymorphism in Women With Suspected Ischemia. , 2018, 2, 8-15.	0.8	1
84	Atherosclerotic cardiovascular disease risk assessment and predictors of statin use in Filipinoâ€American Women. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 632-639.	0.7	1
85	Optimal systolic blood pressure and reduced long-term mortality in older hypertensive women with prior coronary events – An analysis from INVESTâ~†. International Journal of Cardiology: Hypertension, 2020, 7, 100052.	2.2	1
86	Optimizing Precision of Hypertension Care to Maximize Blood Pressure Control: A Pilot Study Utilizing a Smartphone App to Incorporate Plasma Renin Activity Testing. Clinical and Translational Science, 2021, 14, 617-624.	1.5	1
87	Acetaminophen-Induced Hypertension: Where Have All the "Safe―Analgesics Gone?. Circulation, 2022, 145, 424-426.	1.6	1
88	Genetic Contributors of Efficacy and Adverse Metabolic Effects of Chlorthalidone in African Americans from the Genetics of Hypertension Associated Treatments (GenHAT) Study. Genes, 2022, 13, 1260.	1.0	1
89	Ethnicity and blood pressure control in patients with diabetes and coronary artery disease. American Journal of Hypertension, 2002, 15, A194.	1.0	0

90 Response to Letter by Barrios and Escobar. Stroke, 2009, 40, .

#	Article	IF	CITATIONS
91	The use of diuretics plus calcium channel blockers for hypertension may be associated with a higher risk of myocardial infarction but not stroke compared with the combination of diuretics plus Â blockers. Evidence-Based Medicine, 2010, 15, 92-93.	0.6	0
92	Home blood pressure monitoring with patient-initiated drug titration reduces blood pressure in high-risk patients with hypertension. Evidence-Based Medicine, 2015, 20, 58-58.	0.6	0
93	Response to: Heterogeneous Treatment Response by Race Cannot Be Claimed in the Absence of Evidence. American Journal of Hypertension, 2020, 33, e2-e2.	1.0	Ο
94	Implications of Polymorphisms in the BCKDK and GATAâ€4 Gene Regions on Stable Warfarin Dose in African Americans. Clinical and Translational Science, 2021, 14, 492-496.	1.5	0
95	Abstract 15465: Precision Medicine Approach to Resistant Hypertension: Genetic Markers of Resistant Hypertension Through a Genome-wide Association Study (GWAS) in the Secondary Prevention of Subcortical Strokes (SPS3). Circulation, 2015, 132, .	1.6	0
96	Abstract 15986: Plasma Microrna Profiling Reveals Potential Biomarkers of Thiazide Response. Circulation, 2020, 142, .	1.6	0